🔗 Share this article

Ministers and senior MPs have raised concerns that the United Kingdom's negotiated accords with Washington are "built on sand." This comes after revelations that a much-touted deal on medicines, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond broad headline terms contained within government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, hailed as a "significant" achievement, exists as an "statement of intent" without a signed legal text. Critics have noted that the public statements from the UK and US governments describe the deal in markedly contrasting terms. The British version emphasizes securing "duty-free access" as a unique achievement, while the American announcement dwells on the expectation for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has made commitments to raise drug prices in return for little more than a assurance from President Trump," stated David Henig, a trade policy analyst. "It is documented he has a tendency for not following through on agreements."

A Pattern of Unreliability

Worries have been heightened by Washington's move to put on ice the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US claimed a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

Additionally, concessions secured for British farmers as part of an initial accord have not been formally signed off by the US, despite a fast-approaching January deadline. "Our understanding is that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have voiced worries that the government's agreements with the US are lacking substance. One minister described the series of agreements as "built on sand," while another framed the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, stated: "Perhaps most shocking than the US approach is the UK government's credulous faith that his administration is a good faith actor. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Ministry sources have sought to reduce the chances of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that unpredictability is part and parcel of dealing with the Trump administration. However, they maintain that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is a solid gain," one official said.

Yet, delays have emerged in carrying out the May tariff agreement. Promised reciprocal agricultural allowances have failed to be approved, and the assurance to "eliminate duties on UK metals" has remains unmet, with tariffs remaining at 25%.

Moving forward, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.